NTRA logo

NATERA INC

NTRANASDAQ
πŸ† #240 by market capEarnings Nov 11 Β· PostUS Equity
$424.34β–² $13.52 (+3.29%)
After hours Β· at close
πŸ””
Track NTRA
Get earnings, price moves & breaking news on Telegram
Track
24hβ–² 3.3%
7dβ–² 2.5%
14dβ–² 7.4%
30dβ–² 3.0%
ytdβ–² 85.3%
1yβ–² 123.8%
🏦Market Cap
$61.16B
Mid Cap
πŸ“ˆRevenue Growth (YoY)
37.8%
High Growth
πŸ“ŠGross Margin
65.2%
High
πŸ’΅FCF Margin
2.6%
Thin
βš–οΈP/S Ratio
21.5x
Expensive
Otter Score
64
Fair

Trading Snapshot

Day Range
$409.50 – $432.01
52-Week Range
$181.00 – $437.41
Volume (shares)
112,928
Avg Volume (shares)
β€”
Shares Outstanding
144.1M
Next Earnings
2026-11-11

Fundamentals Snapshot

Annual Revenue
$2.31B
Last Q Revenue
$753M
P/E Ratio
β€”
P/S Ratio
21.5x
EPS (TTM)
$-1.37
Dividend Yield
β€”
Dilution (1yr)
+9.6%
NTRA logo

NATERA INC

NTRA
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$2.3Bβ–² +35.9% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
64.8%β–² +7.6% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
βˆ’$310Mβ–² +39.4% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$109Mβ–² +57.6% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
136.7Mβ–² +9.6% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$862Mβ–² +$103M YoY
StockOtter Β· stockotter.space

About NATERA INC

Natera, Inc. is a diagnostics company focused on developing and commercializing a wide array of molecular testing services globally. Its portfolio includes several key offerings: Panorama, a non-invasive prenatal test (NIPT) that screens for chromosomal abnormalities in a fetus using a blood sample from the mother, and also determines zygosity in twin pregnancies. Vistara, designed to identify single-gene disorders by screening for specific single-gene mutations. Horizon, a comprehensive carrier screening test to determine an individual's carrier status for various genetic diseases. Spectrum, utilized during in vitro fertilization (IVF) cycles to detect chromosomal anomalies or inherited genetic conditions. Anora, a miscarriage analysis product that examines fetal chromosomes to help understand the cause of pregnancy loss. Non-invasive paternity testing, which establishes paternity during gestation using blood samples from both the pregnant mother and the alleged father. Beyond reproductive health, Natera also provides specialized tests: Signatera, a sophisticated circulating tumor DNA (ctDNA) technology capable of screening for a generic set of mutations, independent of the individual's specific tumor characteristics. Prospera, a test used to assess and monitor organ transplant rejection. Additionally, the company offers Constellation, a cloud-based software platform that provides laboratory clients with access to Natera's proprietary algorithms and bioinformatics, enabling them to validate and launch their own tests. Natera distributes its products through a direct sales team and an extensive network of approximately 100 laboratory and distribution partners. The company has strategic partnerships, including one with BGI Genomics Co., Ltd. for the development, manufacturing, and commercialization of NGS-based genetic testing assays, and another with Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. Founded in 2003, Natera, Inc. is headquartered in Austin, Texas. It was formerly known as Gene Security Network, Inc. before changing its name in 2012.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Fair
64/100
Analyst data unavailable.

Latest News & Updates

News unavailable.